Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02902120 · ClinicalTrials.gov registry record · Phase 4
HCV Treatment Immune Response With Grazoprevir/Elbasvir Before or After Renal Transplant
A Phase 4 study, sponsored by University of Maryland, Baltimore.
- Completed
- Registry status
- Phase 4
- Development phase
- 21
- Enrollment target
NCT02902120 is a Phase 4 study that has completed, run by University of Maryland, Baltimore. The registered enrollment target is 21 participants.
The verdict
NCT02902120, a Phase 4 study, has completed, sponsored by University of Maryland, Baltimore.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 21 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether patients treated for chronic hepatitis C (HCV) with zepatier (grazoprevir/elbasvir) prior to kidney transplant will have a stronger immune response compared to patients treated after kidney transplant. 25 patients with chronic kidney disease (CKD) and HCV will be treated with zepatier and 25 kidney transplant recipients with chronic kidney disease will be treated with zepatier. Blood markers of immune function will be monitored in both groups to determine their response to therapy.
Interventions
- DRUG Post-transplant Grazoprevir and Elbasvir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2017-05-01 |
| Est. Completion | 2022-06-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02902120
The ClinicalTrials.gov registry entry for NCT02902120 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Post-transplant Grazoprevir and Elbasvir is the first listed.
NCT02902120 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02902120 about?
NCT02902120 is a clinical study titled "HCV Treatment Immune Response With Grazoprevir/Elbasvir Before or After Renal Transplant". The purpose of this study is to determine whether patients treated for chronic hepatitis C (HCV) with zepatier (grazoprevir/elbasvir) prior to kidney transplant will have a stronger immune response compared to patients treated after kidney transplant. 25 patients with chronic kidney disease (CKD) an...
What is the current status of trial NCT02902120?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 21 participants. The study started on 2017-05-01. Estimated completion is 2022-06-08.
What interventions are being tested in trial NCT02902120?
The interventions under investigation include: Post-transplant Grazoprevir and Elbasvir (DRUG).
Who is sponsoring clinical trial NCT02902120?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.